CELIA
OREJA GUEVARA
Profesora asociada de Ciencias de la Salud
Hospital General Universitario Gregorio Marañón
Madrid, EspañaPublicacións en colaboración con investigadores/as de Hospital General Universitario Gregorio Marañón (25)
2024
-
Clinical characteristics and impact on patient-reported outcomes and quality of life of people with ambulatory secondary progressive multiple sclerosis: Discover study
Multiple Sclerosis and Related Disorders, Vol. 90
-
Consensus statement of the Spanish Society of Neurology on the treatment of multiple sclerosis and holistic patient management in 2023
Neurologia, Vol. 39, Núm. 2, pp. 196-208
-
Investigating the 2023 MOGAD Criteria in Children and Adults With MOG-Antibody Positivity Within and Outside Attacks
Neurology, Vol. 103, Núm. 6
2023
-
Monitoring response to disease-modifying treatment in multiple sclerosis
Neurology Perspectives, Vol. 3, Núm. 2
-
XV Reunión Post-ECTRIMS: revisión de las novedades presentadas en el Congreso ECTRIMS 2022 (I)
Revista de neurologia, Vol. 77, Núm. 1, pp. 19-30
-
XV Reunión Post-ECTRIMS: revisión de las novedades presentadas en el Congreso ECTRIMS 2022 (II)
Revista de neurologia, Vol. 77, Núm. 2, pp. 47-60
2022
-
Baseline Inflammatory Status Reveals Dichotomic Immune Mechanisms Involved In Primary-Progressive Multiple Sclerosis Pathology
Frontiers in immunology, Vol. 13, pp. 842354
-
Early predictive risk factors for dimethyl fumarate-associated lymphopenia in patients with multiple sclerosis
Multiple Sclerosis and Related Disorders, Vol. 59
2021
-
Risk and outcomes of COVID-19 in patients with multiple sclerosis
European Journal of Neurology, Vol. 28, Núm. 11, pp. 3712-3721
-
XIII Reunión Post-ECTRIMS: revisión de las novedades presentadas en el Congreso ECTRIMS 2020 (I)
Revista de neurologia, Vol. 72, Núm. 11, pp. 397-406
-
XIII Reunión Post-ECTRIMS: revisión de las novedades presentadas en el Congreso ECTRIMS 2020 (II)
Revista de neurologia, Vol. 72, Núm. 12, pp. 433-442
2020
-
Spanish real-world experience with fingolimod in relapsing-remitting multiple sclerosis patients: MS NEXT study
PLoS ONE, Vol. 15, Núm. 4
-
Three-Year Effectiveness of Dimethyl Fumarate in Multiple Sclerosis: A Prospective Multicenter Real-World Study
CNS Drugs, Vol. 34, Núm. 12, pp. 1275-1286
-
Tolerability and safety of dimethyl fumarate in relapsing multiple sclerosis: a prospective observational multicenter study in a real-life Spanish population
Journal of Neurology, Vol. 267, Núm. 8, pp. 2362-2371
2019
-
Immune tolerance in multiple sclerosis and neuromyelitis optica with peptide-loaded tolerogenic dendritic cells in a phase 1b trial
Proceedings of the National Academy of Sciences of the United States of America, Vol. 116, Núm. 17, pp. 8463-8470
-
Review of the novelties presented at the 2018 ECTRIMS congress: 11th post-ECTRIMS meeting (II)
Revista de Neurologia, Vol. 68, Núm. 11, pp. 468-479
-
Review of the novelties presented at the 2018 ectrims congress: 11th post-ectrims meeting (I)
Revista de Neurologia, Vol. 68, Núm. 10, pp. 431-441
2017
-
Multimarker risk stratification approach at multiple sclerosis onset
Clinical Immunology, Vol. 181, pp. 43-50
-
Revisión de las novedades del XXXII Congreso ECTRIMS 2016, presentadas en la IX Reunión Post-ECTRIMS (II)
Revista de Neurologia, Vol. 65, Núm. 2, pp. 75-84
-
Revisión de las novedades del XXXII congreso ectrims 2016, presentadas en la ix reunión post-ectrims (I)
Revista de Neurologia, Vol. 65, Núm. 1, pp. 31-40